Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 6/20 | 0.76 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CNR1 | P21554 | 3/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4445371 | 0.87 | NSD2 (1.00) | NSD2HTTALDH1A1LMNACNR1 | |
| Hydrochloric Acid SCHEMBL4448809 | 0.85 | NSD2 (1.00) | NSD2HTTALDH1A1LMNACNR1 | |
| SCHEMBL13763413 | 0.83 | NSD2 (0.74) | NSD2ALDH1A1LMNA | |
| SCHEMBL6486861 | 0.81 | NSD2 (0.59) | NSD2HTTALDH1A1LMNACNR1 | |
| SCHEMBL29162296 | 0.81 | NSD2 (0.73) | NSD2HTTALDH1A1LMNACNR1 | |
| SCHEMBL8359828 | 0.81 | NSD2 (0.58) | NSD2HTTALDH1A1LMNACNR1 | |
| SCHEMBL7073805 | 0.80 | CA9 (0.58) | NSD2HTTALDH1A1LMNACNR1 | |
| SCHEMBL7072077 | 0.80 | CA12 (0.74) | NSD2HTTALDH1A1CNR1TSHR | |
| SCHEMBL30230094 | 0.80 | NSD2 (0.57) | NSD2HTTALDH1A1CNR1CYP19A1 | |
| SCHEMBL3659182 | 0.79 | ALDH1A1 (0.88) | HTTALDH1A1LMNACYP19A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849648-B2 | Phenylene alkyne matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1434585-A1 | ALKYNE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20030144274-A1 | Alkyne matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2003-07-31 | — | — | US | disclosed |
| WO-2003032999-A1 | ALKYNE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003032999-A1 | ALKYNE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-24 | — | — | WO | disclosed |
| US-6156746-A | 1,2,5-benzothiadiazepine-1,1-dioxides with n-2 imidazolylalkyl substituents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144274-A1 | Alkyne matrix metalloproteinase inhibitors | MMP11, MMP13, MMP3 | NSD2 3950/4885HTT 1717/4885ALDH1A1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.